| Stefan Leroy Kaiser, MD | |
|
1101 9th St. N, Essentia Health Virginia Clinic, Virginia, MN 55792 | |
| (218) 741-0150 | |
| Not Available |
| Full Name | Stefan Leroy Kaiser |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine |
| Experience | 18 Years |
| Location | 1101 9th St. N, Virginia, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609037324 | NPI | - | NPPES |
| 1609037324 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 53591 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Essentia Health Virginia | Virginia, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Duluth Clinic Ltd | 2567374283 | 932 |
News Archive
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
CYTOGENIX, INC. announced today that it has engaged the Hall Group, P.C. of Dallas, Texas, to conduct the necessary financial audits to bring CytoGenix, Inc. current on all of its required SEC filings and enable it to move onto the NASDAQ.
Aspen Technology, Inc., a leading provider of software and services to the process industries, today announced financial results for its fourth quarter and fiscal year 2010, ended June 30, 2010.
Sangamo Therapeutics, Inc. and Pfizer Inc. today announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo's four lead product candidates, which Sangamo expects will enter the clinic this quarter.
ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company will enter a collaborative R&D agreement with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan), which could offer new hepatocyte derived from human iPS (induced pluripotent stem) cells used for an effective in-vitro drug screening for hepatic toxicity and liver metabolism.
› Verified 3 days ago
| Entity Name | The Duluth Clinic Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902563638 PECOS PAC ID: 2567374283 Enrollment ID: O20031103000229 |
News Archive
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
CYTOGENIX, INC. announced today that it has engaged the Hall Group, P.C. of Dallas, Texas, to conduct the necessary financial audits to bring CytoGenix, Inc. current on all of its required SEC filings and enable it to move onto the NASDAQ.
Aspen Technology, Inc., a leading provider of software and services to the process industries, today announced financial results for its fourth quarter and fiscal year 2010, ended June 30, 2010.
Sangamo Therapeutics, Inc. and Pfizer Inc. today announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo's four lead product candidates, which Sangamo expects will enter the clinic this quarter.
ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company will enter a collaborative R&D agreement with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan), which could offer new hepatocyte derived from human iPS (induced pluripotent stem) cells used for an effective in-vitro drug screening for hepatic toxicity and liver metabolism.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stefan Leroy Kaiser, MD 1101 9th St. N, Essentia Health Virginia Clinic, Virginia, MN 55792 Ph: (218) 741-0150 | Stefan Leroy Kaiser, MD 1101 9th St. N, Essentia Health Virginia Clinic, Virginia, MN 55792 Ph: (218) 741-0150 |
News Archive
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
CYTOGENIX, INC. announced today that it has engaged the Hall Group, P.C. of Dallas, Texas, to conduct the necessary financial audits to bring CytoGenix, Inc. current on all of its required SEC filings and enable it to move onto the NASDAQ.
Aspen Technology, Inc., a leading provider of software and services to the process industries, today announced financial results for its fourth quarter and fiscal year 2010, ended June 30, 2010.
Sangamo Therapeutics, Inc. and Pfizer Inc. today announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo's four lead product candidates, which Sangamo expects will enter the clinic this quarter.
ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company will enter a collaborative R&D agreement with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan), which could offer new hepatocyte derived from human iPS (induced pluripotent stem) cells used for an effective in-vitro drug screening for hepatic toxicity and liver metabolism.
› Verified 3 days ago